Post-marketing safety surveillance of tofacitinib over 9 years in patients with psoriatic arthritis and rheumatoid arthritis

Post-marketing safety surveillance of tofacitinib over 9 years in patients with psoriatic arthritis and rheumatoid arthritis

<p><strong><i>Introduction:</i></strong> The safety of tofacitinib in psoriatic arthritis (PsA) and rheumatoid arthritis (RA) has been demonstrated in clinical studies of ≤ 4 and 9.5 years, respectively. Post-marketing surveillance (PMS) data for tofacitinib from sponta...

Descripció completa

Dades bibliogràfiques
Autors principals:	Burmester, GR, Coates, LC, Cohen, SB, Tanaka, Y, Vranic, I, Nagy, E, Lazariciu, I, Chen, A-S, Kwok, K, Fallon, L, Kinch, C
Format:	Journal article
Idioma:	English
Publicat:	Springer Nature 2023

Ítems similars

Post-Marketing Safety Surveillance of Tofacitinib over 9 Years in Patients with Psoriatic Arthritis and Rheumatoid Arthritis
per: Gerd R. Burmester, et al.
Publicat: (2023-07-01)

Correction: Post-Marketing Safety Surveillance of Tofacitinib over 9 Years in Patients with Psoriatic Arthritis and Rheumatoid Arthritis
per: Gerd R. Burmester, et al.
Publicat: (2023-12-01)

The effect of tofacitinib on residual pain in patients with rheumatoid arthritis and psoriatic arthritis
per: Dougados, M, et al.
Publicat: (2022)

The effect of tofacitinib on residual pain in patients with rheumatoid arthritis and psoriatic arthritis
per: Maxime Dougados, et al.
Publicat: (2022-11-01)

Efficacy of tofacitinib in reducing pain in patients with rheumatoid arthritis, psoriatic arthritis or ankylosing spondylitis
per: Iain B McInnes, et al.
Publicat: (2020-02-01)

Influenza Adverse Events in Patients with Rheumatoid Arthritis, Ulcerative Colitis, or Psoriatic Arthritis in the Tofacitinib Clinical Development Programs
per: Kevin L. Winthrop, et al.
Publicat: (2022-12-01)

The effect of tofacitinib on residual pain in patients with psoriatic arthritis
per: Dougados, M, et al.
Publicat: (2020)

Risk Stratification of Patients with Psoriatic Arthritis and Ankylosing Spondylitis for Treatment with Tofacitinib: A Review of Current Clinical Data
per: Lars Erik Kristensen, et al.
Publicat: (2024-05-01)

Time to response for clinical and patient-reported outcomes in patients with psoriatic arthritis treated with tofacitinib, adalimumab, or placebo
per: Gladman, DD, et al.
Publicat: (2022)

Efficacy and Safety of Tofacitinib in Patients with Psoriatic Arthritis or Ankylosing Spondylitis by Cigarette Smoking Status
per: Alexis Ogdie, et al.
Publicat: (2024-09-01)

Psoriatic arthritis - Tofacitinib as a new treatment
per: Marta Skorupska, et al.
Publicat: (2024-06-01)

Effectiveness of Tofacitinib in Patients Initiating Therapy for Psoriatic Arthritis: Results from the CorEvitas Psoriatic Arthritis/Spondyloarthritis Registry
per: Philip J. Mease, et al.
Publicat: (2024-01-01)

Persistence of Tofacitinib in the Treatment of Rheumatoid Arthritis in Open‐Label, Long‐Term Extension Studies up to 9.5 Years
per: Janet E. Pope, et al.
Publicat: (2019-04-01)

Tofacitinib improves composite endpoint measures of disease in patients with psoriatic arthritis
per: Helliwell, P, et al.
Publicat: (2018)

Fracture in clinical studies of tofacitinib in rheumatoid arthritis
per: Karen E. Hansen, et al.
Publicat: (2022-12-01)

Median time to pain improvement in patients with psoriatic arthritis treated with tofacitinib
per: de Vlam, K, et al.
Publicat: (2018)

Psoriasis, psoriatic arthritis, and rheumatoid arthritis: Is all inflammation the same?
per: Coates, L, et al.
Publicat: (2016)

THE PLACE OF TOFACITINIB IN THE TREATMENT STRATEGY OF RHEUMATOID ARTHRITIS
per: V. I. Mazurov, et al.
Publicat: (2018-05-01)

Psoriatic arthritis: prospects for the future
per: Hackett, S, et al.
Publicat: (2022)

Measuring outcomes in psoriatic arthritis
per: Ogdie, A, et al.
Publicat: (2020)

Time to response for clinical and patient-reported outcomes in patients with psoriatic arthritis treated with tofacitinib, adalimumab, or placebo
per: Dafna D. Gladman, et al.
Publicat: (2022-02-01)

Pharmacokinetic boosting to enable a once-daily reduced dose of tofacitinib in patients with rheumatoid arthritis and psoriatic arthritis (the PRACTICAL study)
per: Céleste J.T. van der Togt, et al.
Publicat: (2022-12-01)

Tofacitinib in the management of active psoriatic arthritis: patient selection and perspectives
per: Ly K, et al.
Publicat: (2019-08-01)

Effect of tofacitinib treatment on active MRI sacroiliitis in psoriatic arthritis patients
per: E. E. Gubar, et al.
Publicat: (2021-05-01)

Outcome measures in psoriatic arthritis: where next?
per: Hackett, S, et al.
Publicat: (2022)

Experience with tofacitinib in the treatment of resistant rheumatoid arthritis
per: A. R. Babaeva, et al.
Publicat: (2015-06-01)

NEW APPROACHES TO PHARMACOTHERAPY OF RHEUMATOID ARTHRITIS: TOFACITINIB
per: E. L. Nasonov
Publicat: (2014-06-01)

Use of YAKVINUS® (tofacitinib) for the treatment of rheumatoid arthritis
per: article Editorial
Publicat: (2018-06-01)

Tofacitinib as monotherapy following methotrexate withdrawal in patients with psoriatic arthritis previously treated with open-label tofacitinib plus methotrexate: a randomised, placebo-controlled substudy of OPAL Balance
per: Nash, P, et al.
Publicat: (2020)

Understanding mediators of pain reduction in psoriatic arthritis patients treated with tofacitinib: role of inflammation
per: Taylor, P, et al.
Publicat: (2019)

Efficacy of tofacitinib for the treatment of psoriatic arthritis: pooled analysis of two phase 3 studies
per: Nash, P, et al.
Publicat: (2018)

Methotrexate in the treatment of rheumatoid arthritis and psoriatic arthritis
per: N. V. Chichasova, et al.
Publicat: (2021-06-01)

Distinguishing rheumatoid arthritis from psoriatic arthritis
per: Joseph F Merola, et al.
Publicat: (2018-08-01)

Psoriatic arthritis
per: FitzGerald, O, et al.
Publicat: (2021)

Relationships between psoriatic arthritis composite measures of disease activity with patient-reported outcomes in Phase 3 studies of tofacitinib
per: Coates, L, et al.
Publicat: (2021)

Efficacy of Tofacitinib for the Treatment of Psoriatic Arthritis: Pooled Analysis of Two Phase 3 Studies
per: Peter Nash, et al.
Publicat: (2018-11-01)

Tofacitinib: Real-World Data and Treatment Persistence in Rheumatoid Arthritis
per: Bertoldi I, et al.
Publicat: (2021-07-01)

Results of studying the clinical efficacy and safety of tofacitinib in the treatment of psoriatic arthritis
per: T. V. Korotaeva, et al.
Publicat: (2019-05-01)

EFFICACY AND SAFETY OF TOFACITINIB IN PATIENTS WITH PSORIATIC ARTHRITIS IN REAL CLINICAL PRACTICE
per: E. Yu. Loginova, et al.
Publicat: (2020-06-01)

Tofacitinib is a modern solution to the problem of resistant rheumatoid arthritis
per: I. V. Menshikova, et al.
Publicat: (2019-05-01)